PDL BioPharma's CEO Discusses Q2 2012 Results - Earnings Call Transcript

PDL BioPharma Inc. (PDLI)

Q2 2012 Results Earnings Call

August 2, 2012 4:30 PM ET

Executives

John McLaughlin – President and CEO

Bruce Tomlinson – Chief Financial Officer

Analysts

Roy Buchanan – JMP Securities

John – RBC Capital Markets

Phil Nadeau – Cowen & Company

Presentation

Operator

Good afternoon. And welcome to the PDL BioPharma's Second Quarter 2012 Earnings Conference Call. Today's call is being recorded.

For opening remarks and introductions, I would now like to turn the call over to Jennifer Williams.

Jennifer Williams

Thank you all for joining us today. I'd like to first point out that there is a slide presentation associated with today's earnings call and you'll see that in the Investor Relations section of the PDL website which you'll find at pdl.com.

Before we begin, let me remind you that the information we will cover today contains forward-looking statements regarding our financial performance and other matters, and our actual results may differ materially from those expressed or implied in the forward-looking statements.

Factors that may cause differences between current expectations and actual results are described in our filings with the Securities and Exchange Commission, copies of which may be obtained in the Investor Section on our website at pdl.com.

The forward-looking statements made during this conference call should be considered accurate only as of the date of this call, and although we may elect to update forward-looking statements from time-to-time in the future, we specifically disclaim any duty or obligation to do so, even as new information becomes available or other events occur in the future.

If you liked this article you might like

Sarepta Pops on Bullish Sentiment Around Duchenne Therapy, PDL Up on Merck Deal: Biotech Movers

Argos Plummets 72%, Leads Biotech Movers

Eli Lilly's Alzheimer's Drug Study Results Are Coming -- Here's What Investors Need to Know

PDL BioPharma (PDLI) Stock Plummets on Q2 Revenue Miss

Today's Weak On High Volume Stock: PDL BioPharma (PDLI)